Business, energy, technology, markets and global industry news from Business News Today

HER3

PharmaDeviceNews HER3
Bispecific T-cell engagers originally developed for blood cancers are being repurposed to eliminate pathogenic B cells and plasma cells in severe autoimmune diseases, raising the possibility of CAR-T-like immune reset without the complexity of individualized cell manufacturing. Representative image.
Pharma & Biotech

World ADC 2026 highlights Invenra’s approach to HER2 and HER3 targeting

Invenra launches 52 Views of Cancer and expands trispecific ADC research targeting HER2 and HER3. See the science and development challenges.

Read More
Akeso has dosed the first patient in a Phase Ib/II study evaluating the HER3 antibody-drug conjugate AK138D1 with ivonescimab in advanced non-small cell lung cancer. Representative image.
Pharma & Biotech

What Akeso’s AK138D1 and ivonescimab combination must prove in advanced NSCLC

Akeso has started a Phase Ib/II lung cancer trial of HER3 ADC AK138D1 with ivonescimab. See what the combination must prove.

Read More
Representative image of a bispecific antibody-drug conjugate in a cancer research setting, illustrating the science behind CStone Pharmaceuticals’ AACR 2026 update on CS5007, CS5006, and CS5008 oncology pipeline candidates.
Pharma & Biotech

Why CStone Pharmaceuticals’ CS5007 may be the most important asset in its AACR 2026 antibody-drug conjugate update

CStone Pharmaceuticals unveiled three ADC programs at AACR 2026. Read what CS5007, CS5006, and CS5008 could mean for oncology development.

Read More